Wishing you all the joys of the season! 
North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030
North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 – Regional Analysis – by Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Mononucleosis, Group A Streptococcus (GAS), and Others) and Laboratory Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the North America Molecular Diagnostics for Infectious Disease Market
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
North America Molecular Diagnostics for Infectious Disease Market Overview
The increasing prevalence of tuberculosis (TB) and rise in awareness of diagnosis and treatment for TB in Mexico is fueling the growth of the molecular diagnosis for infectious diseases market. According to StopTB Partnership Organization, the number of people suffering from TB rose from 30,000 in 2019 to 31,000 in 2020. The growing focus of Centers for Disease Control and Prevention (CDC) has established several international laboratory projects in Mexico. These projects include two projects for the detection of drug-sensitive and drug-resistant TB cases in Sonora and Baja California, Mexico. The common goal of these two projects is to build capacity for state and national disease control program to identify the group at risk and conduct rapid TB tests on that group. These initiatives for screening the masses for TB are creating awareness in the Mexican population. In addition, the extensively growing pharmaceuticals industry, developing healthcare infrastructure, and elevating demand for diagnostic testing products bolster the molecular diagnostics for infectious diseases market growth in Mexico. In February 2021, the World Health Organization (WHO) announced significant advancements in the diagnosis of TB and drug resistance in children, adolescents, and adults. The three new classes of technologies announced for testing TB were as follows:
– Moderate-complexity automated Nucleic Acid Amplification Tests (NAATs) for the diagnosis of TB and detection of variants resistant to rifampicin and isoniazid
– Low-complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents
– High-complexity hybridization-based NAATs for the detection of resistance to pyrazinamide.
North America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
North America Molecular Diagnostics for Infectious Disease Market Segmentation
The North America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger North America molecular diagnostics market for infectious disease market share in 2022.
The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022.
Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.
Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics for infectious disease market in 2022.
Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America molecular diagnostics for infectious disease market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030, registering a CAGR of 12.2% from 2022 to 2030. Molecular diagnostics for infectious diseases in personalized medicine and surging prevalence of infectious disease globally are among the critical factors attributed to the North America molecular diagnostics for infectious disease market expansion.
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
On the contrary, limitations associated with molecular testing hampers the growth North America molecular diagnostics for infectious disease market.
Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 59.4% share of North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,987.25 million. It is projected to garner US$ 4,832.75 million by 2030 to expand at 11.7% CAGR during 2022-2030.
The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 89.7% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,217.88 million. It is projected to garner US$ 3,184.59 million by 2030 to expand at 12.8% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 89.5% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 1,777.99 million. It is projected to garner US$ 4,280.28 million by 2030 to expand at 11.6% CAGR during 2022-2030.
Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 44.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 607.98 million. It is projected to garner US$ 1,567.72 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 33.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 672.52 million. It is projected to garner US$ 1,600.55 million by 2030 to expand at 11.4% CAGR during 2022-2030.
Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 57.3% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 778.27 million. It is projected to garner US$ 2,064.47 million by 2030 to expand at 13.0% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 38.0% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 754.24 million. It is projected to garner US$ 1,927.77 million by 2030 to expand at 12.4% CAGR during 2022-2030.
Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 50.1% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 680.13 million. It is projected to garner US$ 1,759.12 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 49.8% share of the North America molecular diagnostics for infectious disease market in 2022, amassing US$ 990.28 million. It is projected to garner US$ 2,357.76 million by 2030 to expand at 11.5% CAGR during 2022-2030.
Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US held 84.2% share of North America molecular diagnostics for infectious disease market in 2022, amassing US$ 2,815.61 million. It is projected to garner US$ 6,999.30 million by 2030 to expand at 12.1% CAGR during 2022-2030.
Key players operating in the North America molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.
In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America molecular diagnostics for infectious disease market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the molecular diagnostics for infectious disease market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Surging Prevalence of Infectious Disease Globally
4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market – North America Market Analysis
5.1 North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
6. North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
6.3.1 Overview
6.3.2 Point-of-Care Testing: North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
6.4.1 Overview
6.4.2 Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by End User
7.1 Overview
7.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
7.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
7.2.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
8. North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
9. North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Disease Type
9.1 Overview
9.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
9.3.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
9.4.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
10. North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Infection Type
10.1 Overview
10.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11. North America Molecular Diagnostic for Infectious Diseases Market – Country Analysis
11.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country
11.1.2.1 US
11.1.2.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.2.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.2.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.2.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.2.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.2.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.2.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.2.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.2.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.2.2 Canada
11.1.2.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.2.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.2.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.2.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.2.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.2.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.2.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.2.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.2.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.2.3 Mexico
11.1.2.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.2.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.2.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.2.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.2.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.2.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.2.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.2.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.2.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.2.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott Laboratories
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 bioMerieux SA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Danaher Corp
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hologic Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens Healthineers AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bruker Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 DiaSorin SpA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. North America Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 8. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 10. North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. US Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 16. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 19. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. US Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 21. US Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. US Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Canada Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 26. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 27. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 28. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 30. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 31. Canada Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 32. Canada Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. Canada Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 34. Mexico Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 35. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 36. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 38. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 39. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 41. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 42. Mexico Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 43. Mexico Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Mexico Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 45. Organic Developments Done By Companies
Table 46. Inorganic Developments Done By Companies
Table 47. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
LIST OF FIGURES
Figure 1. North America Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. North America Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 6. Point-of-Testing: North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 10. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 11. North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 12. North America: Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue (2022) (US$ Million)
Figure 13. North America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 14. US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 15. Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – North America Molecular Diagnostics for Infectious Disease Market
1. Abbott Laboratories
2. bioMerieux SA
3. Bruker Corp
4. Danaher Corp
5. DiaSorin SpA
6. F. Hoffmann-La Roche Ltd
7. Hologic Inc
8. Siemens Healthineers AG
9. Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.